The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

Thursday, August 30, 2012

Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation15:36 EDT Thursday, August 30, 2012 CAMBRIDGE, Mass. (Business Wire) -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESS™ at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 26759985. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com or the Forest website at www.frx.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting August 30, 2012 at approximately 5:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on September 6, 2012. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 26759985. The archived webcast will be available on Ironwood's website for 14 days beginning approximately one hour after the call. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. LINZESS (linaclotide), Ironwood's guanylate cyclase-C (GC-C) agonist, is an FDA-approved drug for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com. About Forest Laboratories, Inc. Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory, gastrointestinal, and pain management medicine. The Company's pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com. Forest Laboratories, Inc.Frank J. Murdolo, 212-224-6714Vice President - Investor Relationsmedia.relations@frx.comorIronwood Pharmaceuticals, Inc.Media Relations:Lisa Buffington, 617-374-5103lbuffington@ironwoodpharma.comorInvestor Relations:Meredith Kaya, 617-374-5082mkaya@ironwoodpharma.com